OutsourcedPharma Live: AustinPx Facility Tour & Capabilities Presentation
Join AustinPx’s Chief Scientific Officer, Dave Miller, for a presentation focusing on our pharmaceutical manufacturing & development capabilities. Dave’s presentation is followed by a virtual facility tour that will take you behind the scenes of our manufacturing areas by AustinPx’s Senior VP, Operations, Justin Keen.
Read MoreKinetiSol Technology: Scale-Up Approach
Justin Keen, AustinPx Sr. VP of Operations’ talk begins with a discusion on phase-appropriate process development objectives, reviewed as they relate to scale and mode changes as product development evolves to deliver clinical trial material and develop the process design space. Process parameter and quality attribute relationships, including those for typical pre and post KinetiSol…
Read MoreWhy KinetiSol Technology is Disrupting Spray Drying
Dave Miller, AustinPx CSO’s (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving drug product properties. Springboarding from these case studies, Dave then focuses on the facility, utilities, and downstream processing requirements for SDDs and contrasts those with…
Read MoreOptimizing Amorphous Solid Dispersions: Overcoming Scale-Up Challenges with Next-Generation Technologies
As the number of poorly soluble molecules entering the pipeline has increased, the application of amorphous solid dispersions development has grown. With the advent of next-generation ASD technologies, like KinetiSol Technology, drug developers are setting new standards in scalability, sustainability and performance. In this webinar, the expert speakers will share their scale-up experiences and perspectives on opportunities to…
Read MoreOral Dosage Innovation for Pediatric Drug Delivery
Pediatric drug development isn’t just about reducing adult doses. It involves unique technical, regulatory, and manufacturing challenges that require creative formulation strategies. In this webinar, experts from AustinPx and Via Therapeutics explore the complex development of clofazimine mini-tablets for pediatric use, covering solubility issues, stability hurdles, and process optimization from early formulation through clinical manufacturing.…
Read MoreHow Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks interview)
In this Xtalks interview, Dr. Justin Keen, Senior Vice President of Operations at AustinPx, explained why scale up is one of the biggest challenges in amorphous dispersion manufacturing and how KinetiSol™ solves it. Traditional technologies like spray drying and hot melt extrusion require controlling multiple transport phenomena at once, which slows timelines and increases cost. KinetiSol…
Read MoreOvercoming Late Stage Formulations & Manufacturing Challenges with KinetiSol Technology
In this Xtalks webinar, Dr. Dave Miller, Chief Scientific Officer at AustinPx, explores how KinetiSol™ Technology helps sponsors overcome the formulation and manufacturing hurdles that often appear late in development. Traditional spray drying methods can introduce variability, high costs, and scale-up challenges, but KinetiSol offers a solvent-free alternative that delivers consistent performance and improved manufacturability.…
Read MoreAustinPx Live Episode 3: From Molecule to Milestone: Fast-Track Formulation
Originally aired on September 25th, 2025 Watch the third session in our AustinPx Live series! Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx approaches conventional formulation to accelerate First-in-Human studies without sacrificing scientific rigor. He’ll highlight how our expertise in powder-in-capsule dosing, phase-appropriate analytical support, and early manufacturability considerations helps sponsors navigate tight…
Read MoreAustinPx Live Episode 6: Re-thinking ASD Development: Designing for Scale from Day One
Originally aired on March 18th, 2026 Chief Technology Officer, Chris Brough, Ph.D., will lead a discussion on what it takes to successfully scale amorphous solid dispersions from early development into manufacturing. He will explore common scale-up challenges across ASD technologies, the data and decisions that matter most as programs move toward GMP, and how early…
Read MoreKinetiSol in Action: Scalable, Sustainable Amorphous Dispersion Manufacturing
See the KinetiSol Compounder in action and learn how AustinPx’s proprietary KinetiSol™ Technology supports amorphous solid dispersion (ASD) development from rapid prototyping through commercial manufacturing. This video highlights how KinetiSol’s solvent-free, fusion-based process forms ASDs in seconds, simplifies scale-up, reduces operational burden, and expands the formulation design space for complex molecules. With a focus on scalability,…
Read MoreData-Driven Development of Clofazimine: A High-Drug Load Pediatric Mini-Tablet
The development of clofazimine pediatric mini-tablets demonstrates a data-driven approach to pharmaceutical development. By leveraging predictive tools and iterative design, AustinPx transformed a formulation-challenged compound into a scalable, patient-friendly product suitable for clinical trials.
Read MoreConverting from a Spray-Dried Dispersion to a KinetiSol Formulation in <5 Months
A Phase 2 oral drug candidate formulated as a spray-dried dispersion faced limitations in bioavailability, pill burden, and solvent-intensive manufacturing. In less than five months, AustinPx converted the program to a KinetiSol™ formulation, achieving a 5x increase in AUC, reducing manufacturing time by 67%, and eliminating organic solvents and secondary processing steps. The result was…
Read MoreHow Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks article)
AustinPx’s Justin Keen, Senior Vice President, Operations explores the scaling up of KinetiSol Technology. This innovative, solvent-free process rapidly transforms active pharmaceutical ingredients into high-quality amorphous solid dispersions, enhancing solubility and bioavailability. KinetiSol simplifies scale-up by controlling a single variable – shear rate – making the transition from lab-scale to commercial production seamless and efficient. Keen…
Read MoreTrends in amorphous solid dispersion drug products approved by the U.S. FDA between 2012 and 2023
In a recent publication, the trends in ASD drug products over a 12-year period from 2012 to 2023 were analyzed. The review highlights the role of AustinPx’s KinetiSol Technology, a solvent-free process that provides significant advantages over traditional methods like spray drying. KinetiSol’s ability to process thermolabile compounds and improve drug stability and bioavailability is emphasized…
Read MoreLess Mess, Less Stress, Best Expressed: A Superior Alternative To Spray Drying
In a recent article, Chris Brough, CTO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Unlike spray drying, which relies on organic solvents and nitrogen, KinetiSol uses a solvent-free process that directly dissolves drugs in polymers, preventing phase separation and enhancing stability and bioavailability. KinetiSol streamlines the scale-up…
Read MoreWinning Strategies For Oral Dosage Form Development And Manufacturing
In a recent article, Dave Miller, CSO of AustinPx, highlights KinetiSol Technology as a superior alternative to spray drying for amorphous solid dispersions (ASDs). Failure to identify a compound’s red flags—bioavailability, stability, processability, etc.—early in development often manifests as program delays or failures. These setbacks can be avoided through complete molecular characterization, which can de-risk development and…
Read MorePushing the Boundaries: Overcoming Formulation and Manufacturing Challenges (eBook w/ Pharmaceutical Technology)
Winning Strategies For Oral Dosage Form Development and Manufacturing. An eBook in partnership with Pharmaceutical Technology. Oral solid dose (OSD) formulation development must adhere to common considerations, such as project timelines, facilitating CDMO/client transparency and overcoming regulatory challenges. However, development’s difficulty often is compounded by numerous factors such as API supply constraints, challenging physiochemical properties,…
Read MoreBuilding Resilience: CDMO Strategies for Drug Supply Chain Stability
In this article, AustinPx CEO Elizabeth Hickman highlights the critical role small-molecule CDMOs play in stabilizing today’s strained pharmaceutical supply chains. With more than 250 essential drugs in shortage, CDMOs must balance agility with scientific rigor to meet rising demand, regulatory pressures, and funding challenges. Hickman explores how high-science, high-touch strategies, scalable manufacturing, and patient-centric…
Read More